Table 2.
Correlation of methylation of SYK, E-cadherin, and TIMP-3 genes with clinicopathological features in patients with HCC. Values of statistical significance are shown in bold face type.
|
% of patients showing a methylated gene |
||||
|---|---|---|---|---|
| Characteristics | No. patients | SYK | E-cadherin* | TIMP-3# |
| Gender | ||||
| Female | 14 | 42.9% (6/14) | 38.5% (5/13) | 53.8% (7/13) |
| Male | 110 | 25.5% (28/110) | 25.3% (25/99) | 40.2% (39/97) |
| P value | 0.205 | 0.329 | 0.382 | |
| Age (years) | ||||
| <40 | 35 | 25.7% (9/35) | 16.1% (5/31) | 38.7% (12/31) |
| 40–60 | 66 | 25.8% (17/66) | 29.0% (18/62) | 42.4% (25/59) |
| >60 | 23 | 34.8% (8/23) | 36.8% (7/19) | 45.0% (9/20) |
| P value | 0.681 | 0.231 | 0.899 | |
| HbsAg | ||||
| Negative | 11 | 18.2% (2/11) | 22.2%(2/9) | 30.0% (3/10) |
| Positive | 113 | 28.3% (32/113) | 27.2% (28/103) | 43% (43/100) |
| P value | 0.726 | 1.000 | 0.516 | |
| Child-Pugh classification$ | ||||
| A | 118 | 26.3% (31/118) | 24.5% (26/106) | 39.0% (41/105) |
| B | 6 | 50.0 (3/6) | 66.7% (4/6) | 100% (5/5) |
| P value | 0.344 | 0.043 | 0.011 | |
| GGT (U/L) | ||||
| <50 | 60 | 30.0% (18/60) | 20.0% (11/55) | 38.2% (21/55) |
| 50 – 100 | 38 | 28.9% (11/38) | 36.1% (13/36) | 44.1% (15/34) |
| >100 | 26 | 19.2% (5/26) | 28.6% (6/21) | 47.6% (10/21) |
| P value | 0.571 | 0.232 | 0.718 | |
| AFP (μg/L) | ||||
| <20 | 35 | 22.9% (8/35) | 38.7% (12/31) | 48.4% (15/31) |
| 20–400 | 43 | 27.9% (12/43) | 23.1% (9/39) | 42.5% (17/40) |
| >400 | 46 | 30.4% (14/46) | 21.4% (9/42) | 35.9% (14/39) |
| P value | 0.748 | 0.208 | 0.571 | |
| Tumor size (cm) | ||||
| <5 | 29 | 17.2% (5/29) | 38.5% (10/26) | 42.3% (11/26) |
| >=5 | 95 | 30.5% (29/95) | 23.3% (20/86) | 41.7% (35/84) |
| P value | 0.234 | 0.137 | 0.954 | |
| Tumor thrombus | ||||
| No | 103 | 28.2% (29/103) | 25.0% (23/92) | 39.3% (35/89) |
| Yes | 21 | 23.8% (5/21) | 35.0% (7/20) | 52.4% (11/21) |
| P value | 0.793 | 0.407 | 0.329 | |
| Satellite nodule | ||||
| No | 86 | 31.4% (27/86) | 27.8% (22/79) | 43.2% (32/74) |
| Yes | 38 | 18.4% (7/38) | 24.2% (8/33) | 38.9% (14/36) |
| P value | 0.190 | 0.817 | 0.686 | |
| Tumor capsule | ||||
| Yes | 45 | 26.7% (12/45) | 28.6% (12/42) | 38.1% (16/42) |
| No or incomplete | 79 | 27.8% (22/79) | 25.7% (18/70) | 44.1% (30/68) |
| P value | 0.877 | 0.826 | 0.557 | |
| Cirrhosis | ||||
| No | 19 | 21.1% (4/19) | 12.5% (2/16) | 38.9% (7/18) |
| Mild | 61 | 23.0% (14/61) | 21.4% (12/56) | 36.4% (20/55) |
| Moderate | 40 | 37.5% (15/40) | 36.1% (13/36) | 45.5% (15/33) |
| Severe | 4 | 25.0% (1/4) | 75.0% (3/4) | 100% (4/4) |
| P value | 0.383 | 0.032 | 0.09 | |
| TNM stage | ||||
| I | 68 | 33.8% (23/68) | 28.6% (18/63) | 43.9% (25/57) |
| II | 11 | 27.3% (3/11) | 20% (2/10) | 27.3% (3/11) |
| III | 45 | 17.8% (8/45) | 25.6% (10/39) | 42.9% (18/42) |
| P value | 0.173 | 0.834 | 0.585 | |
*
Methylation of E-cadherin was non-informative in 12 cases.
#
Methylation of TIMP-3 was non-informative in 14 cases.
$
No patients with Child-Pugh class C were studied.